Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at 41st Annual J.P. Morgan Healthcare Conference Transcript

Jan 10, 2023 / 06:30PM GMT
Release Date Price: €25.73 (-0.54%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Denali. Little change from last time we were here in person. We're not going to switch rooms for Q&A. We're going to go seamlessly into Q&A after the presentation. You can raise your hand and someone will bring you a microphone or you can enter your question electronically on the portal, I'll send it to an iPad up there, and I can ask the management team.

So with that, let me pass it over to Denali's CEO of Ryan Watts.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Thank you, Jess. It's great to be back in person. It's great to see so many familiar faces, friends collaborators and friendly competitors looking forward to dive into some data today for our programs. It's such an exciting time to be in biotech. Actually, it's a very exciting time to be in neuroscience in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot